MX2016011865A - Composiciones farmaceuticas de compuestos terapeuticamente activos. - Google Patents

Composiciones farmaceuticas de compuestos terapeuticamente activos.

Info

Publication number
MX2016011865A
MX2016011865A MX2016011865A MX2016011865A MX2016011865A MX 2016011865 A MX2016011865 A MX 2016011865A MX 2016011865 A MX2016011865 A MX 2016011865A MX 2016011865 A MX2016011865 A MX 2016011865A MX 2016011865 A MX2016011865 A MX 2016011865A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
active compounds
therapeutically active
treating cancer
compounds
Prior art date
Application number
MX2016011865A
Other languages
English (en)
Inventor
Gu Chong-Hui
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2016011865A publication Critical patent/MX2016011865A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invención se refiere a compuestos y composiciones farmacéuticas útiles para tratar cáncer y otros métodos para tratar cáncer que comprenden administrar a un sujeto en necesidad del mismo un compuesto o composición farmacéutica descrita en la presente.
MX2016011865A 2014-03-14 2015-03-13 Composiciones farmaceuticas de compuestos terapeuticamente activos. MX2016011865A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461953480P 2014-03-14 2014-03-14
PCT/US2015/020346 WO2015138837A1 (en) 2014-03-14 2015-03-13 Pharmaceutical compositions of therapeutically active compounds

Publications (1)

Publication Number Publication Date
MX2016011865A true MX2016011865A (es) 2017-04-13

Family

ID=54072439

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016011865A MX2016011865A (es) 2014-03-14 2015-03-13 Composiciones farmaceuticas de compuestos terapeuticamente activos.
MX2021001739A MX2021001739A (es) 2014-03-14 2016-09-13 Composiciones farmaceuticas de compuestos terapeuticamente activos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021001739A MX2021001739A (es) 2014-03-14 2016-09-13 Composiciones farmaceuticas de compuestos terapeuticamente activos.

Country Status (27)

Country Link
US (1) US20170007661A1 (es)
EP (1) EP3116491B1 (es)
JP (3) JP6524119B2 (es)
KR (1) KR102458157B1 (es)
CN (2) CN106163507B (es)
AU (2) AU2015229212B2 (es)
BR (3) BR112016021012B1 (es)
CA (1) CA2942070A1 (es)
CY (1) CY1125205T1 (es)
DK (1) DK3116491T3 (es)
EA (2) EA202090098A1 (es)
ES (1) ES2881858T3 (es)
HR (1) HRP20211233T1 (es)
HU (1) HUE055209T2 (es)
IL (1) IL247721B (es)
LT (1) LT3116491T (es)
MA (1) MA39725B1 (es)
MX (2) MX2016011865A (es)
NZ (1) NZ723860A (es)
PH (1) PH12016501788B1 (es)
PL (1) PL3116491T3 (es)
PT (1) PT3116491T (es)
RS (1) RS62178B1 (es)
SI (1) SI3116491T1 (es)
UA (1) UA122962C2 (es)
WO (1) WO2015138837A1 (es)
ZA (1) ZA201606134B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
KR20240010105A (ko) 2014-03-14 2024-01-23 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
US10653710B2 (en) 2015-10-15 2020-05-19 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
CA3216701A1 (en) 2015-10-15 2017-04-20 Les Laboratoires Servier Combination therapy for treating malignancies
JP6892448B2 (ja) 2015-12-04 2021-06-23 アジオス ファーマシューティカルズ， インコーポレイテッド 悪性腫瘍の処置の方法
US11241455B2 (en) 2016-01-15 2022-02-08 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods of treating disease by metabolic control of T-cell differentiation
JP6856657B2 (ja) * 2016-02-26 2021-04-07 アジオス ファーマシューティカルズ， インコーポレイテッド 血液学的悪性疾患および固形腫瘍の処置のためのｉｄｈ１阻害剤
EP3535025B1 (en) 2016-11-02 2023-06-28 University of Cincinnati Composition comprising r-2-hydroxyglutarate and one agent that inhibits myc signaling for treating cancer
AU2018210141A1 (en) * 2017-01-20 2019-08-29 Constellation Pharmaceuticals, Inc. Solid dispersions of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
CA3076405A1 (en) 2017-09-22 2019-03-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystalline sulfamide compound
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
MX2021000068A (es) * 2018-07-06 2021-03-25 Agios Pharmaceuticals Inc Formas y composiciones farmaceuticas de ivosidenib.
US20210069113A1 (en) * 2019-09-11 2021-03-11 Modavar Pharmaceuticals LLC Solid unit dosage form for dose individualized drug delivery
WO2022036033A2 (en) 2020-08-12 2022-02-17 Servier Pharmaceuticals, Llc Solid state forms of an organic compound
US20230414515A1 (en) 2020-10-02 2023-12-28 Lonza Bend Inc. Acetic acid as processing aid in spray drying for basic drugs

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343548B2 (en) * 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
MX2009006806A (es) * 2006-12-22 2009-08-27 Vertex Pharma Secado por rocio fluidizado.
US20100273808A1 (en) * 2008-11-21 2010-10-28 Millennium Pharmaceticals, Inc. Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
US20120121515A1 (en) * 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
CN102573485B (zh) * 2009-06-08 2014-11-26 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
US8652534B2 (en) * 2009-10-14 2014-02-18 Berry Pharmaceuticals, LLC Compositions and methods for treatment of mammalian skin
TWI557123B (zh) * 2010-10-21 2016-11-11 梅迪維新技術公司 結晶型（８Ｓ，９Ｒ）－５－氟－８－（４－氟苯基）－９－（１－甲基－１Ｈ－１，２，４－三唑－５－基）－８，９－二氫－２Ｈ－吡啶并［４，３，２－ｄｅ］呔－３（７Ｈ）－酮甲苯磺酸鹽
CN102827170A (zh) * 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN115536635A (zh) * 2012-01-06 2022-12-30 法国施维雅药厂 治疗活性化合物及其使用方法
US9474779B2 (en) * 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2014015422A1 (en) * 2012-07-27 2014-01-30 Ontario Institute For Cancer Research Cellulose-based nanoparticles for drug delivery
WO2015127173A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
PL3116491T3 (pl) 2022-02-07
ZA201606134B (en) 2024-01-31
HUE055209T2 (hu) 2021-11-29
EP3116491A4 (en) 2017-11-15
PT3116491T (pt) 2021-08-10
MX2021001739A (es) 2021-04-19
JP2017508804A (ja) 2017-03-30
BR122023021436A2 (pt) 2023-12-12
BR112016021012B1 (pt) 2024-01-23
WO2015138837A1 (en) 2015-09-17
CN106163507B (zh) 2020-06-26
AU2019232825B2 (en) 2021-08-05
CA2942070A1 (en) 2015-09-17
KR102458157B1 (ko) 2022-10-24
HRP20211233T1 (hr) 2021-10-29
EP3116491A1 (en) 2017-01-18
EA034366B1 (ru) 2020-01-31
JP2021088605A (ja) 2021-06-10
BR112016021012A2 (pt) 2018-08-07
IL247721B (en) 2020-04-30
UA122962C2 (uk) 2021-01-27
NZ723860A (en) 2023-04-28
SI3116491T1 (sl) 2021-12-31
EA201691844A1 (ru) 2016-12-30
JP2019163278A (ja) 2019-09-26
RS62178B1 (sr) 2021-08-31
MA39725B1 (fr) 2021-09-30
EP3116491B1 (en) 2021-05-05
CN112206232A (zh) 2021-01-12
DK3116491T3 (da) 2021-08-09
CY1125205T1 (el) 2023-03-24
EA202090098A1 (ru) 2020-11-30
CN106163507A (zh) 2016-11-23
JP6524119B2 (ja) 2019-06-05
KR20160124907A (ko) 2016-10-28
AU2019232825A1 (en) 2019-10-10
US20170007661A1 (en) 2017-01-12
IL247721A0 (en) 2016-11-30
AU2015229212A1 (en) 2016-09-22
BR122023021440A2 (pt) 2023-12-12
AU2015229212B2 (en) 2019-06-20
ES2881858T3 (es) 2021-11-30
LT3116491T (lt) 2021-08-10
PH12016501788A1 (en) 2016-12-19
PH12016501788B1 (en) 2016-12-19

Similar Documents

Publication Publication Date Title
PH12016501790A1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12019501197A1 (en) Therapeutically active compounds and their methods of use
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
TW201613901A (en) New compounds
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
TN2017000554A1 (en) Novel combination for use in the treatment of cancer
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
PH12016502352A1 (en) Pharmaceutical composition
WO2015003355A3 (en) Therapeutically active compounds and their methods of use
TW201613578A (en) Pharmaceutical combinations
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
SG11201605868XA (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX363378B (es) Composiciones nanoparticuladas y formulaciones de compuestos de piperazina.
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
NZ762611A (en) Pharmaceutical compositions of therapeutically active compounds